These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9869561

  • 21. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

  • 22. Activity of amoxicillin-clavulanate against penicillin-resistant Streptococcus pneumoniae in an experimental respiratory infection model in rats.
    Smith GM, Slocombe B, Abbott KH, Mizen LW.
    Antimicrob Agents Chemother; 1998 Apr; 42(4):813-7. PubMed ID: 9559788
    [Abstract] [Full Text] [Related]

  • 23. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [Abstract] [Full Text] [Related]

  • 24. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA.
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [Abstract] [Full Text] [Related]

  • 26. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM, Prause JL, Danziger LH, Pendland SL.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.
    Isla A, Trocóniz IF, Canut A, Labora A, Martín-Herrero JE, Pedraz JL, Gascón AR.
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):167-73. PubMed ID: 21334779
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.
    Gisby J, Wightman BJ, Beale AS.
    Antimicrob Agents Chemother; 1991 May; 35(5):831-6. PubMed ID: 1854164
    [Abstract] [Full Text] [Related]

  • 30. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F, Klossek JM, Peynegre R, Serrano E, Castillo L, Bobin S, Desprez D, Renault C, Neel V, Rouffiac E, Borie C.
    Presse Med; 2002 Oct 19; 31(34):1596-603. PubMed ID: 12426976
    [Abstract] [Full Text] [Related]

  • 31. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J.
    J Antimicrob Chemother; 2004 Dec 19; 54(6):1148-51. PubMed ID: 15489246
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec 19; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 33. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN.
    Int J Antimicrob Agents; 2005 Apr 19; 25(4):282-9. PubMed ID: 15784306
    [Abstract] [Full Text] [Related]

  • 34. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov 19; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. In vivo activity of amoxicillin/clavulanic acid and erythromycin in experimental otitis media caused by Streptococcus pneumoniae plus Haemophilus influenzae.
    Parra A, Ponte C, Cenjor C, García-Olmos M, Giménez MJ, Aguilar L, Soriano F.
    Int J Antimicrob Agents; 2004 Jan 19; 23(1):25-31. PubMed ID: 14732310
    [Abstract] [Full Text] [Related]

  • 38. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B, Soubirou JF, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A.
    Antimicrob Agents Chemother; 2016 Jan 19; 60(1):424-30. PubMed ID: 26525800
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
    Poirier R.
    Presse Med; 1998 Sep 19; 27 Suppl 4():14-5. PubMed ID: 9798478
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.